Abstract Body

Background

Accurate and rapid objective tools are needed to detect non-adherence to daily oral HIV regimens and support timely transitions to long-acting injectables. RESTRICT is an HIV reverse transcriptase inhibition assay that has been calibrated to estimate tenofovir diphosphate (TFV-DP) concentrations in whole blood. We evaluated the clinical accuracy of RESTRICT compared with liquid chromatography–tandem mass spectrometry (LC-MS/MS) – the gold standard for monitoring real-world long-term adherence.

Methods

We conducted a cross-sectional study among adults on stable tenofovir-based antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) at two Seattle clinics. Fresh whole blood was tested by RESTRICT, and paired dried blood spots were analyzed for TFV-DP by LC-MS/MS. We assessed correlations between RESTRICT (average normalized fluorescence) and LC-MS/MS (fmol/3mm punch), and evaluated RESTRICT accuracy with Receiver Operating Characteristics analysis for detecting poor (<4 doses/week) and suboptimal adherence (<daily dosing) based on LC-MS/MS benchmarks for tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), respectively.

Results

We enrolled 150 participants (100 ART, 50 PrEP); median age was 53.8 years, and 92% were male. TDF was used by 80% of PrEP and 8% of ART participants. Based on LC-MS/MS, 72% had TFV-DP consistent with daily dosing, while 23% were taking 4-6 doses/week. RESTRICT fluorescence correlated strongly with TFV-DP concentrations among TDF users (Pearson r = –0.92, 95% CI: –0.95 to –0.86) and moderately among TAF users (r = –0.69, 95% CI: –0.78 to –0.57). For detecting poor adherence with TDF, a fluorescence cutoff >0.19 achieved sensitivity of 100% (95% CI: 100–100%), specificity of 98% (95% CI: 93–100%) and Area Under the Curve (AUC) of 0.99 (95% CI: 0.95–1.00). For detecting suboptimal adherence with TAF, a cutoff >0.60 yielded 85% sensitivity (95% CI: 69–96%), 87% specificity (95% CI: 79–95%), and 0.92 AUC (95% CI: 0.86–0.97).

Conclusions

The RESTRICT assay demonstrated strong correlation with TFV-DP by LC-MS/MS and high accuracy for detecting poor or suboptimal adherence to tenofovir-based oral PrEP and ART regimens. With simpler preparation and faster turnaround time than LC-MS/MS, the RESTRICT assay may be a practical test to monitor daily oral adherence and transitions to long-acting injectables.

Table or Figure